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The role of cell adhesion molecules in mediating interactions with neighboring cells and the extracellular
matrix has long been appreciated. More recently, these molecules have been shown to modulate intracellular
signal transduction cascades critical for cell growth and proliferation. Expression of adhesion molecule on glia
(AMOG) is downregulated in human and mouse gliomas, suggesting that AMOG may be important for growth
regulation in the brain. In this report, we examined the role of AMOG expression on cell growth and intra-
cellular signal transduction. We show that AMOG does not negatively regulate cell growth in vitro or in vivo.
Instead, expression of AMOG in AMOG-deficient cells results in a dramatic increase in cell size associated
with protein kinase B/Akt hyperactivation, which occurs independent of phosphatidylinositol 3-kinase activa-
tion. AMOG-mediated Akt phosphorylation specifically activates the mTOR/p70S6 kinase pathway previously
implicated in cell size regulation, but it does not depend on tuberous sclerosis complex/Ras homolog enriched
in brain (Rheb) signaling. These data support a novel role for a glial adhesion molecule in cell size regulation
through selective activation of the Akt/mTOR/S6K signal transduction pathway.
Cues received from the extracellular environment by mem-
brane receptors influence diverse intracellular signaling path-
ways that regulate cell survival, differentiation, and growth.
Cell adhesion molecules have been primarily implicated in
maintaining cell-cell and cell-matrix interactions important
for maintaining tissue integrity. However, recent evidence
indicates that these adhesion molecules, like other mem-
brane-localized receptors, can influence intracellular signal
transduction (34, 61). Numerous adhesion molecules, includ-
ing cadherins, integrins, and immunoglobulin-like adhesion
molecules, modulate these signaling pathways’ effects on cell
growth and proliferation.
In the central nervous system (CNS), altered expression of a
number of cellular adhesion molecules has been associated
with brain tumor formation, including neural cell adhesion
molecule (NCAM), the L1 adhesion molecule, and multiple
members of the cadherin family. Increased expression of
NCAM, a member of the immunoglobulin superfamily, has
been implicated in invasion of glioma cells (47). Upon cluster-
ing of the 140-kDa NCAM protein by homophilic binding or
interactions with heparan sulfate proteoglycans, the NCAM
cytoplasmic tail activates the Ras/mitogen-activated protein
(MAP) kinase (MAPK) signaling cascade (56), which likely
contributes to increased tumor proliferation. In addition, over-
expression of the L1 adhesion molecule in high-grade gliomas
promotes cell-matrix and intercellular interactions and facili-
tates glioma cell migration (33, 59). Similarly, numerous mem-
bers of the cadherin family have been implicated in brain
tumor formation. N-cadherin promotes oligodendrocyte mi-
gration and adhesion to astrocytes (57), and E-cadherin ex-
pression in WC5 rat astrocyte-like cells results in increased cell
adhesion and decreased cell motility (14). Expression of an-
other cadherin protein, cadherin 11, was shown to be de-
creased in gliomas, where it has been implicated in tumor
invasion (79). In this regard, our laboratory has shown that
T-cadherin, a novel cadherin protein lacking the catenin intra-
cellular binding domain, functions as a glioma growth regula-
tor (30). In these studies, T-cadherin was reduced in mouse
and human gliomas, and its re-expression in T-cadherin-defi-
cient glioma cells resulted in a p21-dependent G2 growth ar-
rest.
Our laboratory has employed a transgenic mouse glioma
model in which activated H-Ras is expressed in astrocytes to
identify novel genetic changes associated with astrocytoma for-
mation (25). Gene expression profiling of neoplastic and non-
neoplastic astrocytes from these mice revealed that another
adhesion molecule expressed in the brain, adhesion molecule
on glia (AMOG), is downregulated in neoplastic cells (25).
Similarly, Senner et al. (60) showed that AMOG expression
was decreased in neoplastic cells in human glioma specimens
relative to normal astrocytes, and that this decrease in expres-
sion correlated with increasing tumor grade. These observa-
tions suggested that AMOG may play a role in regulating
glioma growth and proliferation.
AMOG was first described as a unique membrane glycopro-
tein mediating neuron and astrocyte adhesion in the central
nervous system, where it has been implicated in neurite out-
growth and neuronal migration (4, 5, 6, 39, 45, 46). AMOG is
first expressed in the brain shortly before granule cell migra-
tion, and its expression increases during early postnatal devel-
opment to reach its highest levels in adult glial cells (48). While
phenotypically normal at birth, Amog-deficient mice develop
* Corresponding author. Mailing address: Department of Neurol-
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motor incoordination and paralysis in early postnatal life and
die 17 to 18 days after birth (44).
Analysis of the predicted amino acid sequence revealed se-
quence similarity between AMOG and the 1 subunit of the
Na/K ATPase (23). This Na/K ATPase enzyme consists
of a catalytic  subunit and a regulatory  subunit (74), and it
is required for the maintenance of ionic homeostasis in most
mammalian cells. AMOG associates with the catalytic  sub-
unit to form a functional ion pump and, therefore, was also
identified as the 2 subunit of the Na/K ATPase (23). In
this regard, this unique molecule serves both cell-cell adhesion
and ion exchange functions.
The role of the Na/K ATPase in cell growth control has
been most extensively studied in cardiac myocytes, where in-
hibition of the ion pump with the cardiac glycoside ouabain
results in myocyte hypertrophy (26, 27, 75). In myocytes ex-
posed to nontoxic concentrations of ouabain, myocyte protein
synthesis increases while the DNA content of the cells remains
unchanged, suggesting that pump inhibition primarily influ-
ences cell growth rather than cell proliferation without af-
fecting intracellular ion concentrations (43). This growth
phenotype was the result of the Na/K ATPase-dependent
alterations in intracellular signaling pathway activation, which
directly contributed to myocyte hypertrophy (26, 27, 36, 75).
Collectively, these data support a role for the Na/K ATPase
or its subunits in regulating cell growth; however, the mecha-
nisms underlying its signaling have not been fully elucidated.
Because AMOG is downregulated in mouse and human
tumors and the Na/K ATPase pump has been implicated in
cell growth control, we sought to define the biological conse-
quence of AMOG re-expression in AMOG-deficient cells and
to characterize the mechanism underlying AMOG-mediated
intracellular signaling. Consistent with its role as an adhesion
molecule, AMOG expression resulted in increased cell aggre-
gation and attachment. Furthermore, our studies show that
AMOG expression in glioma cells results in a dramatic in-
crease in cell soma size, which is associated with hyperactiva-
tion of the mTOR/p70S6 kinase (S6K) signal transduction
pathway. In addition, AMOG increases Akt activation inde-
pendent of phosphatidylinositol 3-kinase (PI3K), and it stim-
ulates ribosomal S6 phosphorylation by a mechanism that
requires mTOR but is independent of the tuberin/hamartin
complex (THC) and the Rheb GTPase protein. These data
provide a link between cell adhesion and cell size regulation
and demonstrate that Akt regulation of the mTOR pathway
can be selectively modulated.
MATERIALS AND METHODS
AMOG cloning and cell culture. RNA was extracted from normal mouse brain
using TRIzol Reagent (Invitrogen, Carlsbad, Calif.), and 3 g of RNA was
subjected to first-strand synthesis using random polyhexamer primers and Su-
perscript II reverse transcriptase (Invitrogen) at 42°C. Two microliters of first-
strand cDNA was PCR amplified using the forward AMOG primer correspond-
ing to bases 574 to 597 (National Center for Biotechnology Information
accession number BC034586; 5GCGGATCCAGTCATCCAGAAAGAGAAG
AAGAGC-3) and the reverse primer corresponding to bases 2224 to 2244
(5TCAGGTTTTGTTGATCCGGAG-3). The AMOG cDNA was cloned into
pCR2.1 using the TA cloning system (Invitrogen) to generate pCR2.1.AMOG.
To generate a tagged AMOG protein, a second forward primer containing a myc
tag at the 5 end (myc tag, bases 3 to 36; 5-GCCATGGAACAAAAACTC
ATCTCAGAAGAGGATCTGGTCATCCAGAAAGAGAAGAAGAG-3)
was used to amplify myc.AMOG from pCR2.1.AMOG. The myc-tagged AMOG
was cloned into pCR2.1 using the TA cloning system and was subcloned into
pcDNA3 at the EcoRI site to generate pcDNA3.myc.AMOG. Gene sequence
was confirmed by direct sequencing using the ABI PRISM dGTP BigDye Ter-
minator ready reaction cycle sequencing kit (version 3.0; Applied Biosytems,
Foster City, Calif.). The protein product of pcDNA3.myc.AMOG plasmid (65
kDa) was identified using the coupled in vitro transcription/translation kit (Pro-
mega, Madison, Wis.) using the anti-AMOG polyclonal antibody (BD Transduc-
tion Laboratories, Lexington, Ky.).
AMOG-expressing and control cell lines were generated by transfecting
U87-MG human glioma cells with either pcDNA3.myc.AMOG or pcDNA3.myc
vector. Stably transfected cells were selected in 500 g of Geneticin (G418)/ml.
Twenty-one clones were screened for AMOG expression by Western blotting.
Two cell lines transfected with the vector (V8 and V9) and three cell lines
expressing AMOG (A4, A13, and A16) were selected for further study. Trans-
fected cells were maintained in Dulbecco’s modified Eagle medium (DMEM)
plus 10% fetal bovine serum (FBS; Invitrogen) supplemented with nonessential
amino acids (Mediatech, Herndon, Va.) and 10 mM sodium pyruvate (Mediat-
ech). For immunofluorescence images, the cytoskeleton was stained with
BODIPY-conjugated phalloidin (0.2 U in 50 l; Molecular Probes, Eugene,
Oreg.) and the nuclei were stained with Hoechst (Molecular Probes).
LY294002 and the farnesyltransferase inhibitor FTI-277 were purchased from
Calbiochem (La Jolla, Calif.). Rapamycin was purchased from Sigma (St. Louis,
Mo.). Cultures containing equal numbers of cells were treated with 10 M
FTI-277, 2 ng of rapamycin/ml, or 20 M LY294002 in DMEM containing 10%
fetal bovine serum for 24 h. Cells were harvested, lysed, and analyzed by Western
blotting as described below. Each experiment was performed at least three times
with comparable results.
Western blotting and antibodies. Cells were washed with cold phosphate-
buffered saline (PBS), scraped, transferred to an Eppendorf tube, and lysed with
cold lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM Na-pyrophosphate, 1 mM -glycerol phos-
phate, 1 mM Na3VO4, 1 g of leupeptin/ml, 1 mM phenylmethylsulfonyl fluoride
[PMSF]). Lysates were centrifuged at 16,000 relative centrifugal forces for 10
min at 4°C. Protein concentrations were determined using the bicinchoninic acid
assay (Pierce, Rockford, Ill.). Equal total protein was loaded on sodium dodecyl
sulfate (SDS)-polyacrylamide gels and transferred to polyvinylidene difluoride
(PVDF) membranes (Immobilon-P; Millipore, Bedford, Mass.). Membranes
were blocked in Tris-buffered saline–Tween 20 (TBS-T) with 5% nonfat dry milk
for 1 h at room temperature. Membranes were then incubated with primary
antibodies in TBS-T with 5% nonfat dry milk or 5% bovine serum albumin (for
phospho antibodies), washed, and incubated with the appropriate secondary
antibody in TBS-T with 5% nonfat dry milk. Chemiluminescence detection was
performed using the ECL reagent (Amersham Biosciences, Arlington Heights,
Ill.). Each experiment was performed at least three times with identical results.
All antibodies are from Cell Signaling Technology (Beverly, Mass.) unless
otherwise indicated. The following commercial primary antibodies were used:
anti-PDK1 (3062), anti-Akt (9272), anti-S6K (9202), anti-S6 (2212), anti-MAPK
(9102), anti-Rheb (4935), anti-P-S6K (9205), anti-P-S6 (2215), anti-P-MAPK
(9101), anti-P-Akt (9271), anti-Gab1 (3232), anti-Na/K ATPase 2 subunit
(AMOG; 610914; BD Transduction Laboratories), anti-Na/K ATPase 3
subunit (N74120; BD Transduction Laboratories), anti-Myc (sc-40; Santa Cruz
Biotechnology, Santa Cruz, Calif.), anti-cleaved caspase 3 (9661), anti-P-src
(2101), anti-P-insulin-like growth factor receptor (IGFR) (Tyr1131/1426; 3021),
anti-P-Tyr (PY20; BD Transduction Laboratories), anti-fibroblast growth factor
receptor-1 (FGFR-1; (34720), anti-epidermal growth factor receptor (EGFR)
(2232), anti-platelet-derived growth factor receptor (PDGFR) (3162), anti-P-
tuberin Ser939, Thr1462, and Tyr1571 (3611, 3614, 3615), anti-P-tyr p85 PI3K
binding motif (3821), and anti--tubulin (T-9026; Sigma). The Na/K ATPase
1 and 3 subunits were identified with polyclonal antibodies to synthetic pep-
tides from the N termini of the subunits. The 2 subunit was identified with an
antibody (McB2) provided by K. Sweadner (Massachusetts General Hospital),
and the Na/K ATPase 1 subunit was identified with an antibody provided by
A. Askari (Medical College of Ohio). Secondary antibodies used were anti-rabbit
horseradish peroxidase (HRP) conjugate (7074) and anti-mouse HRP conjugate
(7076).
Rubidium-86 uptake. Cells were grown to 70% confluency in 12-well dishes
and were washed with 1.5 ml of medium containing 145 mM NaCl, 2.5 mM KCl,
1.5 mM MgSO4, 2 mM Na2HPO4, 1 mM CaCl2, 25 mM HEPES, pH 7.40 (buffer
A). Cells were resuspended in buffer A containing 0.1 mM bumetanide with 0.1
mM ouabain as indicated. After 5 min, the solution was aspirated and replaced
with 250 l of the corresponding solution containing 86Rb (1.5  105 cpm). At
various time points (0 to 10 min), the flux medium was aspirated and the cells
were washed three times with 2.5 ml of 116 mM MgCl2 at 4°C. Cells were
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dissolved by the addition of 300 l of 0.1 M NaOH–0.1% 3-[(3-cholamidopro-
pyl)-dimethylammonio]-1-propanesulfonate. Radioactivity in 200-l samples was
determined by liquid scintillation. The protein concentration of each well was
determined using bovine serum albumin as standard and the Bio-Rad Protein
Assay reagent as described by the supplier (Hercules, Calif.).
Growth assays. To assess log-phase growth, 105 cells were plated in 60-mm-
diameter culture dishes, and cell numbers for each clone were determined by
direct counting on a hemacytometer at days 3, 6, and 9.
To measure DNA synthesis, thymidine incorporation assays were performed.
For these experiments, 105 vector-transfected or AMOG-expressing cells were
plated in 6 wells of a 24-well plate. After 24 h, the medium was changed to
serum-free DMEM and was incubated at 37°C for 24 h. The medium was
aspirated and replaced with serum-free DMEM containing 1 mCi of [3H]thymi-
dine (Amersham Biosciences, Piscataway, N.J.)/ml and incubated at 37°C for 4 h.
Cells were washed twice with PBS and solubilized in 200 mM NaOH. Disinte-
grations per minute (dpm) were determined in a Liquid Scintillation Beta An-
alyzer (Packard Instruments Co., Meridan, Conn.), and the mean and standard
deviation was determined for each cell line. Each experiment was repeated three
times with similar results.
To measure cell growth in vivo, AMOG-expressing clones (A4 and A16) and
vector-transfected (V8 and V9) cells were trypsinized and resuspended in Ma-
trigel at a final concentration of 107 cells/ml. One-hundred microliters was
injected into the flanks of 6- to 8-week old male immunocompromised athymic
nu/nu mice. Four mice were injected with each clone. All procedures followed
the Interdisciplinary Principles and Guidelines for the Use of Animals in Re-
search, Marketing, and Education, issued by the New York Academy of Sciences’
Ad Hoc Committee on Animal Research. The tumor volumes were measured
with calipers for 3 weeks after injection. Tumor volume was calculated according
to the formula tumor volume (in cubed millimeters)  (L  W2)/2, where L
represents the longest dimension and W the shortest dimension of the tumor.
Half of each tumor was homogenized and lysed in MAPK lysis buffer. One-
hundred micrograms of total protein from each tumor was analyzed by Western
blotting to confirm AMOG expression. The experiment was repeated twice with
identical results.
Aggregation assays. Cells were washed with Ca2- and Mg2–free PBS twice
and digested with 0.05% trypsin containing 0.5 mM Ca2. The cells were washed
with HCMF (10 mM HEPES [pH 7.4], 0.137 M NaCl, 5.4 mM KCl, 0.34 mM
Na2HPO4 · 12H2O, 0.1% glucose) while on ice, as previously described. Cells
were resuspended at 105 cells per 0.5 ml of HCMF. In quadruplicate, 0.5 ml of
the cell suspension was seeded in the wells of a 24-well plate that was precoated
with 1% bovine serum albumin (BSA). Ca2 was added to a final concentration
of 1 mM. The plates were placed in a 37°C shaker and rotated at 80 rpm for 1 h.
Cells were fixed with 0.5 ml of 8% paraformaldehyde on ice for 15 min. The wells
were gently stirred to prevent cells from settling. The number of aggregates (3
cells/cluster) and single cells were counted with a hemacytometer. To calculate
the aggregation index, the total number of particles (aggregates and single cells)
was divided by the total number of cells in the suspension. The assay was
repeated three times with identical results.
Cell adhesion. Cell adhesion was analyzed as described previously (30). A
96-well plate was precoated with fibronectin (10 g/ml; Sigma) in sterile PBS at
4°C overnight. The wells were washed twice with PBS and incubated with 2%
heat-inactivated BSA for 2 h at 37°C. The cells were digested with 0.05% trypsin
containing 0.5 mM CaCl2, resuspended at a density of 106 cells/ml in serum-free
DMEM, and incubated for 2 h at 37°C. Cells (100 l) were added to each well
and allowed to adhere for 1 or 4 h. At the end of the incubation period, cells were
washed three times with PBS and stained with 0.5% crystal violet for 30 min at
room temperature. After being washed, 50 l of 1% sodium dodecyl sulfate was
added to each well overnight at room temperature. The number of adherent cells
was quantitated by absorbance at 540 nm. Each experiment was repeated at least
three times with identical results.
Flow cytometry. Cultured cells were trypsinized, fixed in 2% formaldehyde–
0.2% glutaraldehyde, RNase A treated, and stained with propidium iodide
according to established protocols. Astrocyte cell size was analyzed using a
FACSCalibur flow cytometer (Becton-Dickinson, San Jose, Calif.). Events were
gated according to forward scatter and side scatter to exclude debris and aggre-
gates. A second gating by FL2-A was then used to select cells in G0/G1, and the
gated events were plotted as a forward-scatter histogram to evaluate cell size.
Each experiment was performed at least three times with identical results.
PI3K activity assay. Vector-transfected (V8) or AMOG-expressing (A16) cells
were cultured to 80% confluency in 100-mm-diameter tissue culture plates and
serum starved overnight. As negative controls, one dish of each cell line was
treated with serum-free DMEM containing 0.5% NP-40 (Sigma) to inhibit PI3K
activity. Culture dishes were washed three times in ice-cold buffer A (137 mM
NaCl, 20 mM Tris-HCl [pH 7.4], 1 mM CaCl2, 1 mM MgCl2, 0.1 mM sodium
orthovanadate). Cells were lysed in 1 ml of buffer A containing 1% NP-40 and 1
mM PMSF at 4°C for 20 min. Cells were scraped, and cellular debris was
removed by high-speed centrifugation at 4°C. Supernatants were incubated with
anti-PI3K antibody (Upstate Biotechnology, Lake Placid, N.Y.) and precipitated
with protein A-agarose beads. Cells were washed sequentially in buffer A con-
taining 1% NP-40, wash buffer (100 mM Tris-HCl [pH 7.4], 5 mM LiCl, and 0.1
mM Na3VO4), and TNE buffer (10 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM
EDTA, and 0.1 mM sodium Na3VO4). To test PI3K activity, the precipitated
enzyme-antibody complex was incubated with 30 Ci of [-32P]dATP (Amer-
sham Biosciences) containing 20 mM MgCl2 in the presence of 20 g of phos-
phatidylinositol (Avanti Polar Lipids, Alabaster, Ala.) in a 37°C shaker (75 rpm)
for 10 min. The reaction was terminated with the addition of 20 l of 6 N HCl.
Lipids were extracted in 160 l of CHCl3:methanol (1:1). Samples were centri-
fuged at 16,100  g for 10 min. Silicon thin-layer chromatography (TLC) plates
were pretreated with 1 mM EDTA–1% potassium oxalate diluted in methanol-
H2O (40:60) and activated at 100°C for 1 h. One microliter of the lower organic
phase from each sample was spotted on the TLC plate and developed by chro-
matography in CHCl3-methanol-H2O-NH4OH (60:47:11.3:2). Plates were al-
lowed to dry, and radiolabeled lipids were visualized by autoradiography and
quantitated by liquid scintillation counting. Each experiment was performed at
least three times with identical results.
siRNA-mediated Rheb inhibition. Rheb siRNA constructs are described else-
where (68). The plasmids p5RIRESGFP (murine stem cell virus [MSCV] vec-
tor) and p	2 helper plasmid were a kind gift from Jason Weber (Washington
University, St. Louis, Mo.). Empty MSCV vector, MSCV-H1non (control), and
MSCV-Rheb653 were cotransfected with pM2 helper vector into the 293T pack-
aging cell line using Lipofectamine 2000 (Invitrogen). The medium was changed
6 h later. Vector-only (V8) or AMOG-expressing (A16) cells were transduced
with the filtered supernatant of the transfected 293T cells in the presence of 10
g of polybrene (Specialty Media, Phillipsburg, N.J.)/ml five times over the
ensuing 60 h. Six hours after the last application of filtered media, the medium
was exchanged for DMEM containing 10% FBS. Twenty-four hours later, the
cells were harvested and lysed, and Western blotting was performed as described
above. Each experiment was performed at least two times with identical results.
RESULTS
AMOG expression in glioma cells does not alter Na/K
ATPase expression or function. To examine the potential role
of AMOG in regulating cell growth and proliferation indepen-
dent of its role as an ion pump subunit, we re-expressed
AMOG in U87-MG glioma cells that do not express endoge-
nous AMOG or have apparent deficits in ionic homeostasis.
We generated several cell lines expressing myc-tagged AMOG
and chose three for further analysis (Fig. 1a). Clones A4 and
A16 expressed high levels of AMOG, while expression was
lower in clone A13. Two vector-transfected cell lines (V8 and
V9) were used as controls. Re-expression of AMOG did not
interfere with protein expression of the other Na/K ATPase
subunits expressed in the brain (Fig. 1b).
While most studies have used ouabain to study the effects of
the Na/K ATPase on cell growth, we evaluated AMOG-
dependent effects directly by expressing AMOG in cells that
lack endogenous AMOG. Present evidence suggests that while
the beta subunit is required for the formation of active enzyme
and the targeting of the alpha subunit to the plasma mem-
brane, it is not directly involved in ion exchange (22). To
ensure that Na/K ATPase pump function was not disrupted
in AMOG-expressing cells, we measured uptake of the K
analog rubidium-86. Rubidium-86 uptake was similar in AMOG-
expressing and control cells (Fig. 1c). This transport was sen-
sitive to ouabain, indicating that ion flux was mediated by the
Na/K ATPase. These data show that expression of AMOG
(2) in 2-deficient cells did not disrupt the expression of
other Na/K ATPase subunits (1, 2, 3, 1, and 3) or
alter the function of the Na/K ATPase ion pump.
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AMOG expression does not alter cellular proliferation in
vitro or in vivo. To determine if AMOG expression altered cell
proliferation, we analyzed cultures during log-phase growth.
When equal numbers of cells were plated and counted after 3,
6, and 9 days in culture, no differences in cell number were
observed (Fig. 2a). Similarly, we observed no differences in
saturation density when cells were grown for 6 days past con-
fluence (data not shown). In addition, [3H]thymidine incorpo-
ration assays showed no significant differences in DNA synthe-
sis between vector control cell lines and those expressing
AMOG (Fig. 2b). Lastly, we observed no differences in DNA
content by flow cytometry (data not shown).
Because the in vivo environment may influence cell prolif-
eration, we tested the ability of these cells to proliferate when
grown as subcutaneous tumor implants in the flanks of immu-
nocompromised athymic (nu/nu) mice. As observed with the in
vitro growth assays, we observed no differences between the
two clones with the highest AMOG expression (A4 and A16)
and the two vector control cell lines (V8 and V9) after 3 weeks
in vivo (Fig. 2c). At the conclusion of the experiment, we
verified AMOG expression in the A4 and A16 lines (data not
shown). These results demonstrate that, both in vitro and in
vivo, AMOG expression does not alter cellular proliferation.
To determine if cell death was altered in AMOG-expressing
glioma cells, we stained cultured cells for cleaved (activated)
caspase 3, a critical mediator of both the extrinsic and intrinsic
apoptotic pathways (9). We observed no consistent differences
in the number of caspase 3-expressing cells (data not shown).
In addition, when equal cell numbers were plated and the
number of live, Trypan blue-excluding cells counted, we ob-
served no differences in the number of surviving cells (data not
shown). Taken together, these data suggest that AMOG does
not regulate cell proliferation or apoptosis.
AMOG expression increases cellular aggregation and at-
tachment. Because AMOG was originally identified as a glial
adhesion molecule, we next analyzed the ability of AMOG-
expressing cells to promote cell aggregation in vitro. When
cells were allowed to aggregate in culture plates pretreated
with BSA to prevent cell attachment, AMOG-expressing cells
formed large cellular aggregates containing 3 cells (Fig. 3a).
To quantitate this observation, the aggregation index was cal-
culated by determining the total particle number (single cells
and aggregates) in suspension cultures. Fewer particles were
present in AMOG-expressing cultures, indicating a higher ten-
dency of these cells to form clusters (Fig. 3b).
To further assess AMOG’s role in adhesion, we analyzed the
ability of these cells to attach to fibronectin-coated plates. At
1 h, attachment to fibronectin was increased in those cells that
expressed high levels of AMOG (A4 and A16; Fig. 3c). These
results confirm AMOG’s role as an adhesion molecule and
FIG. 1. Stable expression of AMOG does not affect cell proliferation in vitro and in vivo. (a) U87 glioma cells were transfected with pcDNA3
or pcDNA3.myc.AMOG and selected in Geneticin to generate stable cell lines. Three cell lines with various levels of AMOG expression (arrow)
were selected for further characterization: A4 (high expression), A13 (low expression), and A16 (high expression). Cells that incorporated the
pcDNA3 vector only (V8 and V9) were used as controls. (b) All three  and  subunits are expressed in mouse brain while the 1 and 1 subunits
are expressed in kidney. Stable expression of AMOG (Na/K ATPase 2 subunit) in clones A4, A13, and A16 did not disrupt expression of the
other Na/K ATPase subunits. The A13 clone expresses low levels of 2 that were detectable with longer film exposures. (c) Function of the
Na/K ATPase was assessed by uptake of the K analog rubidium-86. K transport was similar in AMOG-expressing (A4 and A16) and control
cells (V9; control). This flux was sensitive to ouabain ( ouabain), indicating that Na/K ATPase mediates K transport in these cell lines
(ouabain sensitive). Similar results were obtained for A13 and V8 cells (data not shown). Each experiment was repeated at least three times with
similar results. Error bars indicate standard deviations.
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demonstrate that AMOG mediates both cell-cell and cell-sub-
strate interactions.
AMOG-expressing cells exhibit an increased cell size. While
no effects of AMOG expression on cell proliferation, apopto-
sis, or motility (data not shown) were observed, we noted a
striking increase in the cell size of the AMOG-expressing cell
lines. Phalloidin staining of the actin cytoskeleton revealed an
increased cell soma size (Fig. 4a). Many of these cells were
multinucleated, as determined by Hoechst staining. In con-
trast, vector-transfected cells were small and singly nucleated.
To provide support for these qualitative observations, equal
numbers of cells were pelleted by centrifugation. The pellets
from the AMOG-expressing cell lines were significantly larger
than those produced from the vector-only stable cell lines (Fig.
4b). In addition, we determined the size distribution of these
cells using forward scatter analysis by flow cytometry. The cell
FIG. 2. AMOG expression does not alter cell proliferation. (a)
Equal numbers of cells were plated and cells were counted during log-
phase growth (days 3, 6, and 9 after plating). There were no significant
differences in cell number between the vector–transfected (V8 and V9)
or AMOG expressing (A4, A13, and A16) stable cell lines at any time
point. (b) Thymidine incorporation assays revealed no significant dif-
ferences in DNA synthesis between the cell lines. (c) Vector-only or
AMOG-expressing cells were injected subcutaneously in the flanks of
6- to 8-week-old nude mice. Tumors volumes were determined weekly
for 3 weeks. At all time points, there was no significant difference in
tumor volume produced from the vector-transfected or the AMOG-
expressing cell lines. Error bars indicate standard deviations.
FIG. 3. AMOG expression increases cellular aggregation and ad-
hesion. (a) When grown in suspension in precoated plates and visualized
by phase-contrast microscopy, AMOG-expressing cells exhibit increased
cell-cell aggregation compared to that of vector-transfected control cells.
(b) The aggregation index was calculated for AMOG-expressing and
vector-transfected cells. A decrease in aggregation index is indicative of an
increased tendency to aggregate. The asterisk denotes a statistically sig-
nification decrease in this index. Error bars indicate standard deviations.
(c) Cell lines expressing high levels of AMOG (clones A4 and A16)
exhibit increased cell adhesion to fibronectin-coated plates 1 h after seed-
ing. The single asterisk denotes a statistically significant increase in
absorbance (Abs) at 540 nm. Error bars indicate standard deviations.
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size histogram demonstrated a right shift compared to control
cells, indicative of an increase in cell size in the AMOG-
expressing cells (Fig. 4c). These results show, using three in-
dependent methods, that AMOG expression results in an in-
creased cell soma size.
Activation of Akt and ribosomal S6 in AMOG-expressing
cells occurs independently of PI3K. Previous work from our
laboratory and others (7, 38, 68) has implicated hyperactiva-
tion of the Akt/mTOR/S6K pathway in cell size regulation in
the brain. To determine whether AMOG expression resulted
in increased Akt/mTOR/S6K pathway activation, we moni-
tored phosphorylation of ribosomal S6 as a surrogate marker
of mTOR pathway hyperactivation. In AMOG-expressing cells,
ribosomal S6 was hyperphosphorylated (Fig. 5a). This effect
was dose dependent, as cells expressing high levels of AMOG
(A4 and A16) expressed more phosphorylated S6 protein than
cells with an intermediate level of AMOG expression (A13). In
contrast, vector-transfected cells have only low levels of phos-
phorylated S6 when grown in medium containing 10% serum or
under conditions of serum starvation (Fig. 5a; data not shown).
The signal transduction cascade downstream of the insulin-
like growth factor-1 receptor (IGF1-R) is known to regulate S6
phosphorylation in both Drosophila melanogaster and mamma-
lian cells (18, 51). This signaling pathway is dependent on
activation of phosphatidylinositol 3-kinase and its downstream
target, Akt. We sought to better understand how AMOG reg-
ulates this pathway by examining activation of the signaling
intermediates. Previous work using ouabain-treated cells has
shown that the Na/K ATPase pump regulates Src activation
(26, 27, 74). Src activation and translocation to the membrane
can, in turn, activate receptor tyrosine kinases (RTKs). Using
phosphospecific antibodies, we determined that there was no
increase in the expression of phosphorylated Src (data not
shown). These results suggest that AMOG regulates this path-
way downstream of Src.
We also examined the phosphorylation status of the IGF1-R
using a phosphospecific antibody and found no differences in
AMOG-expressing cells compared to controls. In addition,
immunoprecipitation of cell lysates with a phosphotyrosine
antibody revealed no differences in the phosphorylation status
FIG. 4. AMOG-expressing cells exhibit increased cell soma size. (a) Fluorescence images of phalloidin-stained actin (green) demonstrate the
increased cellular size of the AMOG-expressing cells (A4 and A16) compared to that of vector-expressing cells (V8). Several of the AMOG-
expressing cells are multinucleated, as shown by Hoescht staining (red). (b) The overall cellular volume was increased in AMOG-expressing cells,
as determined by centrifugation of 2.5 million cells from each cell line and directly visualizing pellet size. (c) Flow cytometry events were collected
for vector (V8 and V9) and AMOG-expressing cells (A4, A13, and A16) and counts were plotted according to forward scatter. The cell size
distribution histogram demonstrates the increased cell size of the AMOG-expressing cells.
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of other RTKs, including platelet-derived growth factor recep-
tor, epidermal growth factor receptor, and fibroblast growth
factor receptor-1 (FGFR-1; data not shown). IGF1-R trans-
duces signals by recruiting and phosphorylating the docking
protein Grb2-associated binder 1 (Gab1) (28). Phosphorylated
Gab1 associates with a variety of downstream effector mole-
cules, including PI3K, to regulate several different biological
processes that include cell proliferation and survival (37).
Western blotting using phospho-specific antibodies specific for
activated Gab1 similarly revealed no differences in activation
between AMOG-expressing and vector control cells (data not
shown). These results demonstrate that AMOG expression
does not alter activation of these growth factor receptors or the
docking protein Gab1.
To establish the level at which AMOG influences this sig-
naling pathway, we examined the activation status of molecules
downstream of RTKs. To determine whether PI3K was con-
stitutively activated in AMOG-expressing cells, we used an in
vitro assay to monitor the ability of immunoprecipitated PI3K
to phosphorylate phosphatidylinositol (PtdIns) to produce the
radioactive lipid product PtdIns3P. We found no difference in
PI3K activity in the AMOG-expressing cells compared to that
of control cells under any of the conditions tested (Fig. 5b).
Similarly, we observed no increase in phosphorylation of PI3K
targets using an antibody that specifically recognizes a PI3K
phosphorylation motif (data not shown). Finally, to determine
whether AMOG expression resulted in activation of the PI3K
target, PDK1, we used phospho-specific PDK1 antibodies and
found no differences in PDK1 activation (Fig. 5c).
However, we did observe a robust increase in the levels of
activated (phosphorylated) Akt in AMOG-expressing cells,
suggesting that AMOG-mediated activation of this pathway
occurs at the level of Akt activation (Fig. 5c). This activation
was dose dependent, as cells expressing intermediate levels of
AMOG (clone A13) exhibited an intermediate level of Akt
activation (Fig. 5a). Consistent with this observation, other
downstream effectors, including S6 kinase and ribosomal S6,
were also hyperactivated in AMOG-expressing cells. Collec-
tively, these results indicate that AMOG regulates this signal-
ing pathway at the level of Akt and that this activation occurs
FIG. 5. AMOG-expressing cells exhibit increased Akt/mTOR/S6 pathway signaling. (a) The increase in cell size was associated with increased
levels of phosphorylated S6 (Ser240/244), as determined by Western blotting, in AMOG-expressing cells (A4 and A16) compared to that of
vector-only controls (V8 and V9). Activation of Akt (Ser473) was assessed using a phosphorylation-specific antibody. Western blotting for tubulin
demonstrates equal protein loading. (b) The enzymatic activity of PI3K was determined in vitro by monitoring the conversion of PtdIns to
PtdIns-3P by lipid extraction and separation by thin-layer chromatography. When vector-transfected or AMOG-expressing cells were serum starved
overnight, there was no difference in PI3K activity. NP-40 eliminates PI3K activity in both cell lines. (c) Activation of the insulin-like growth factor
receptor signaling pathway, as determined by Western blotting with phosphospecific antibodies, revealed that AMOG expression is associated with
an increase in phosphorylated Akt (Ser473), S6K (Thr389), and S6 (Ser240/244). Upstream targets of this pathway, including PDK1 (Ser241) and
MAPK (Thr202/Tyr204), were not activated in the AMOG-expressing cells. Expression of these proteins was not altered in AMOG expressing
cells, as demonstrated by immunoblotting with antibodies that detect both phosphorylated and nonphosphorylated forms of these proteins.
Immunoblotting for tubulin serves as a loading control. All experiments were repeated at least three times with comparable results.
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independently of PI3K or PDK1 activation. This finding sug-
gests a new mechanism for Akt regulation, similar to that re-
ported for the phosphatidylinositol kinase enhancer A (PIKE-
A) protein, which binds to and activates Akt independent of
PI3K activity (2). To determine if AMOG-mediated Akt acti-
vation influenced other Akt-regulated signaling pathways, we
examined MAPK activation by immunoblotting with an anti-
body specific for phosphorylated MAPK. We observed no dif-
ferences in MAPK activation in AMOG-expressing cells (data
not shown). These data support a model in which AMOG-
mediated Akt activation preferentially activates the mTOR/
S6K signaling cascade to modulate cell size.
Akt-mediated activation of ribosomal S6 is mTOR-depen-
dent but occurs independently of signaling by the THC com-
plex and Rheb. Recent evidence suggests that Akt regulates
ribosomal S6 activation through the tuberin/hamartin complex
(THC) (16, 52, 64), and that tuberin directly inhibits activation
of the mTOR/S6K pathway by functioning as a GTPase-acti-
vating protein (GAP) for a Ras-like molecule, Ras-homolog
enriched in brain (Rheb), to prevent mTOR activation (16, 31,
55, 62, 72). Present models suggest that Akt phosphorylates
tuberin to inactivate the THC, resulting in hyperactivation of
the mTOR/S6K pathway. We examined the phosphorylation
status of tuberin, in light of reports that Akt activation results
in tuberin phosphorylation on residues Ser939, Thr1463, and
Tyr1572 (16, 32, 52, 65). No hyperphosphorylation (inactiva-
tion) of tuberin on any of these amino acid residues was ob-
served in AMOG-expressing cells (data not shown), suggesting
that AMOG-induced Akt and S6 activation do not involve
inactivation of the THC.
To determine whether AMOG-mediated regulation of this
pathway was dependent on known downstream effector mole-
cules, we inhibited Rheb, mTOR, and S6K using both phar-
macologic and genetic inhibition. We used the farnesyltrans-
ferase inhibitor FTI-277 to inhibit Rheb. Previous work has
shown that Rheb is a farnesylated protein and that this mod-
ification is critical for its function (11, 15). When AMOG-
expressing cells were treated with 10 M FTI-277 for 24 h, we
observed no decrease in S6 activation by Western blotting (Fig.
6a). This concentration of drug has been shown to completely
ameliorate S6 activation in hamartin-deficient astrocytes in
which the THC is disrupted (68). In contrast, rapamycin treat-
ment (2 ng/ml) inhibits mTOR activation and results in com-
plete amelioration of S6 hyperactivation in AMOG-expressing
cells. Similarly, S6 activation in control cells was sensitive to
rapamycin, supporting the role of mTOR in growth-factor-
mediated activation of this pathway. Finally, we used low doses
of LY294002 (20 M) to selectively inhibit the function of S6K
but not PI3K (1), and we found complete blockade of S6, but
not Akt, activation in AMOG-expressing and control cells (Fig.
6a). Phosphorylation of MAPK or Akt was not altered in cells
treated with FTI-277, rapamycin, or LY294002 (Fig. 6a and
data not shown). These data suggest that S6 activation in these
cells operates through a pathway that is dependent on Akt and
mTOR.
Farnesyltransferase inhibitors can influence other signaling
pathways, including those regulated by other Ras family mem-
bers (58). To directly determine whether S6 activation in these
cells was Rheb independent, we inhibited Rheb expression
using a previously generated siRNA construct. We used mu-
rine stem cell virus to deliver Rheb-specific siRNA (Rheb653)
or a control construct (H1) to AMOG-expressing and vector-
only control cells. This genetic approach has been shown to
efficiently inhibit S6 activation in Tsc1-deficient astrocytes (68).
Transduction with the Rheb siRNA inhibited Rheb expression
and S6 phosphorylation in the control cells but did not reverse
S6 hyperactivation in the AMOG-expressing cells (Fig. 6b).
Moreover, this Rheb siRNA specifically targets Rheb1 and not
Rheb2. While both Rheb1 and Rheb2 mRNA are expressed in
U87 cells by quantitative reverse transcription-PCR (RT-PCR)
(data not shown), these results suggest that Rheb1 is the pri-
mary Rheb molecule involved in THC signaling in glioma cells.
Coupled with the pharmacologic data, these results support a
Rheb-independent mechanism of S6 activation in AMOG-ex-
pressing cells (Fig. 6c).
DISCUSSION
Cellular adhesion molecules play numerous important roles
both in maintaining tissue integrity via extracellular interac-
tions and by modulating intracellular signal transduction path-
ways important for cellular homeostasis. Altered expression of
these adhesion molecules can disrupt intracellular signals im-
portant for cell growth regulation and contribute to tumor
formation (12). Although adhesion molecules have been im-
plicated in brain tumor formation, little is known about the
specific intracellular signals that these molecules modulate.
We have examined the role of the nervous system astrocyte
adhesion molecule AMOG in cell growth control and intracel-
lular signal transduction in light of recent observations that this
molecule is downregulated in both human and mouse brain
tumors.
We examined the effect of AMOG re-expression on several
cellular properties important for brain tumor formation and
progression, including cell proliferation, cell adhesion, cell mi-
gration, and cell size. Previous studies using the cardiac glyco-
side ouabain to partially inhibit the Na/K ATPase support a
role for this ion pump in regulating cell growth rather than cell
proliferation (29, 36, 49, 75). In these studies, ouabain-induced
inhibition increased the expression of a number of growth-
related genes and stimulated nonproliferative cell growth (hy-
pertrophy). Similarly, Senner et al. (60) showed that AMOG
expression in AMOG-deficient C6 glioma cells did not reduce
cell proliferation. Instead, AMOG expression increased cell
adhesion and decreased cell migration on Matrigel. These re-
sults are consistent with our results with U87 human glioma
cells, in which we did not observe any effects of AMOG re-
expression on glioma proliferation or apoptosis in vitro and in
vivo. Collectively, these data show that AMOG does not mod-
ulate cell proliferation in vitro or in vivo and raise the possi-
bility that AMOG modulates other tumor-associated proper-
ties, such as cell adhesion and motility.
Adhesion molecules mediate homophilic and heterophilic
cellular interactions with neighboring cells and with the extra-
cellular matrix (ECM). Consistent with the role of AMOG as
an adhesion molecule, our data show that AMOG expression
promotes homophilic aggregation. Furthermore, AMOG-ex-
pressing cells exhibit increased cell-substrate interactions, such
as attachment to fibronectin. The mechanism underlying these
cell-cell and cell-substrate interactions remains unknown, be-
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cause the putative AMOG receptor has not yet been identified.
Previous studies have shown that AMOG has a unique extra-
cellular domain and does not bind to NCAM and L1. In this
regard, AMOG-mediated adhesion is not inhibited by antibod-
ies to either NCAM or L1 (4, 5).
The study by Senner and colleagues (60) using a single
AMOG-expressing glioma cell line showed that AMOG ex-
pression in glioma cells decreases cell motility. We assessed the
migration of several cell lines with various levels of AMOG
expression by using a Boyden chamber assay (data not shown).
However, the large size of the AMOG-expressing cells im-
peded their movement through the 8-m-pore-size membrane
barriers and through Matrigel. Although we cannot rule out a
direct effect on cell motility, the most striking phenotype of
AMOG-expressing cells in our experiments was a dramatic
increase in cell size. Because cell size was not specifically ad-
dressed by Senner et al., it is possible that changes in cell size
also contributed to observed decreases in cell motility in their
study.
The increase in cell soma size observed in our AMOG-
expressing cells was reminiscent of cellular phenotypes ob-
served in Drosophila mutants in which various components of
the insulin signaling pathway, including the insulin receptor
(dinr) (13), insulin receptor substrate 1 (chico) (8, 24), and
PI3K (Dp110) (40, 72), are disrupted (71). Insulin receptor-
mediated PI3K activation generates inositol lipids that stimu-
late a variety of downstream effectors important for cell growth
and proliferation. One of these targets, the kinase PDK1, re-
FIG. 6. Pharmacologic and genetic inhibition of the mTOR/S6K pathway reveals Rheb-independent regulation in AMOG-expressing cells. (a)
Vector-only (V8 and V9) and AMOG-expressing (A4 and A16) cells were treated with the following inhibitors for 24 h: FTI-277 (10 nM),
rapamycin (2 nM), and low-dose LY294002 (20 M). Activation of ribosomal S6 by phosphorylation (Ser240/244) was used as a marker of pathway
activation. Untreated cells show high levels of activated S6. Inhibition of Rheb with the farnesyltransferase inhibitor FTI-277 did not alter P-S6
levels. Inhibition of mTOR with rapamycin or inhibition of S6K with low-dose LY294002 completely blocked activation of S6. Activation of Akt
(Ser473) was assessed using a phosphorylation-specific antibody. Western blotting for AMOG is shown as a control. Blotting for tubulin dem-
onstrated equal protein loading (data not shown). (b) Genetic inactivation of Rheb by siRNA (R653) did not alter S6 activation in AMOG-
expressing cells but did eliminate S6 activation in vector-only cells. As a negative control, cells were transduced with a construct containing the H1
promoter alone (H1). Tubulin immunoblots are shown as loading controls. (c) AMOG regulates Akt by a mechanism that occurs independently
of PI3K. AMOG-mediated Akt activation preferentially influences mTOR/S6K signaling that regulates cell size. AMOG-dependent activation of
this pathway requires mTOR but occurs independently of THC and Rheb signaling, suggesting that the molecular input (i.e., AMOG) to Akt
differentially influences activation of specific downstream pathways.
VOL. 25, 2005 CELL SIZE REGULATION BY AMOG 3159
 o
n
 January 6, 2014 by W








cruits Akt to the cell membrane and phosphorylates Akt on
threonine-308 (3, 53, 70). In addition to insulin receptor-me-
diated PI3K activation, other growth factor receptor tyrosine
kinases (RTKs) and their associated adaptor proteins, includ-
ing Src and Gab1, activate PI3K and result in Akt phosphor-
ylation (9). In addition, focal adhesion kinase (FAK) relays
integrin-mediated signals to PI3K/Akt in response to the ECM
(10, 73). Importantly, numerous adhesion molecules have been
shown to regulate PI3K/Akt signaling. E-cadherin, an integral
membrane glycoprotein important for homophilic interactions
at adherens junctions, activates this pathway by recruiting
PI3K to E-cadherin protein complexes (14). Similarly, intra-
cellular adhesion molecule 2 (ICAM-2)-dependent ezrin phos-
phorylation in immune cells recruits PI3K to the cell mem-
brane, promoting production of inositol lipids and activating
PDK1 and Akt (50). Expression of the melanoma-associated
adhesion molecule (MelCAM) recruits FAK to a focal adhe-
sion complex, resulting in PI3K activation (41).
Insights into alternative mechanisms of Akt activation have
derived from recent studies on a unique molecule termed PI3K
enhancer (PIKE). PIKE is a nuclear GTPase that exists as
three isoforms: PIKE-S (short form), PIKE-L (long form), and
PIKE-A, as a result of alternative splicing (PIKE-S and -L) or
the use of an alternative transcription initiation site (PIKE-A).
PIKE-S and PIKE-L bind to PI3K via a proline-rich N-termi-
nal domain and stimulate its lipid kinase activity, resulting in
Akt activation (77). PIKE-A, however, lacks this N-terminal
domain and instead binds directly to and activates Akt (2).
These results indicate that, while most known activators rely on
PI3K-dependent mechanisms of Akt phosphorylation, Akt ac-
tivation can occur independently of PI3K. In this regard, heat
shock, oxidative stress, and cytosolic Ca2 have been shown to
activate Akt and are insensitive to pharmacologic PI3K inhib-
itors (70).
In this study, we identify AMOG as an adhesion molecule
that regulates Akt (Fig. 6c). In contrast to signal transduction
mediated by other adhesion molecules, AMOG-mediated reg-
ulation of Akt signaling does not involve activation of RTKs or
RTK-associated proteins. Similar to PIKE-A-mediated signal-
ing, AMOG activates Akt independently of PI3K. It is possible
that AMOG directly activates Akt; however, we were unable to
demonstrate any biochemical interaction between AMOG and
Akt, as had been reported for PIKE-A. Alternative routes to
Akt activation might involve other signaling intermediates that
bind AMOG and subsequently activate Akt. Further studies
will be required to define the molecular interactions that fa-
cilitate AMOG activation of Akt.
While many inputs influence Akt activation via PI3K-depen-
dent and -independent mechanisms, the downstream targets of
Akt signaling are equally diverse. Akt activation modulates
numerous cellular processes, including apoptosis, prolifera-
tion, differentiation, and nutrient metabolism (18, 70). Central
to its role in regulating cell growth, Akt has been shown to
phosphorylate tuberin to inactivate the THC, resulting in in-
creased activation of the Rheb/mTOR/S6K pathway (11, 16,
21, 31, 32, 62). Loss of Tsc1 or Tsc2 in both Drosophila and
mammalian cells results in an increase in cell size but does not
influence cell number (20, 32, 51, 63, 68). However, recent
studies suggest that Akt growth regulation does not require Tsc
expression in Drosophila, suggesting that Akt signaling includes
both THC-dependent and -independent pathways (17). Acti-
vation of S6K and its target, ribosomal S6, results in increased
translation of key components of the translational machinery,
including ribosomal proteins and elongation factors (9). Hy-
peractivation of this pathway, therefore, increases protein pro-
duction, resulting in increased cell soma size. In this regard,
pharmacologic inhibition of mTOR signaling results in re-
duced protein translation and decreased cell soma size (38).
The importance of mTOR signaling to cell size regulation is
underscored by our finding that the AMOG-induced increase
in S6 phosphorylation is inhibited by treatment with rapamycin
and low-dose LY294002 for 24 h. While prolonged rapamycin
treatment has been shown to partially rescue the cell size
defects in Tsc1-deficient astrocytes (68), this lengthy exposure
was associated with significant cellular toxicity in glioma cells,
precluding detailed analysis of this cellular phenotype in the
presence of these pharmacologic agents.
Using two complementary approaches, our studies demon-
strate that AMOG-mediated activation of the mTOR/S6K sig-
naling pathway occurs independently of Rheb GTPase activa-
tion. Previous studies examining the effect of farnesylation on
Rheb function have shown that farnesylation-defective Rheb
mutants exhibit compromised ability to activate S6K (11, 42,
66) and that Rheb farnesylation is required for cell cycle pro-
gression and amino acid uptake in yeast (69, 76). In our ex-
periments, cells were treated with FTI-277 for 24 h. This treat-
ment was sufficient to completely block S6 activation in control
cells but not in AMOG-expressing glioma cells. However, it is
possible that previously synthesized, farnesylated protein per-
sisted in these cells to permit S6 activation. To address this, we
used a genetic approach to inhibit Rheb. Again, S6 activation
was completely blocked in control cells treated with Rheb
siRNA but not in AMOG-expressing cells. While it remains
formally possible that the low level of persistent Rheb expres-
sion following siRNA-mediated inhibition is responsible for S6
activation, our studies both in control U87-MG glioma cells
and primary astrocytes (Fig. 6) (68) indicate that the level of
Rheb inhibition achieved using this siRNA approach is suffi-
cient to completely block S6 activation in these cells. These
observations, coupled with the use of two independent exper-
imental approaches to assess the Rheb dependence of mTOR/
S6K activation in glioma cells, support our conclusion that
stimulation of this signaling pathway by AMOG occurs primar-
ily by a Rheb-independent mechanism.
In addition to modulating the mTOR/S6K pathway, Akt
regulates expression of the cyclin-dependent kinase inhibitor
p27Kip1, a negative regulator of cell proliferation and size.
p27Kip1 inhibits formation of the cyclin E/cyclin-dependent
kinase 2 complex that is required for the G1-to-S cell cycle
transition. p27Kip1 expression is decreased in cells that overex-
press Akt or lack Tsc1 expression. In Tsc1-deficient astrocytes,
our laboratory has found that decreased expression of p27Kip1
is associated with a decrease in contact inhibition growth arrest
(67). Moreover, mice lacking p27Kip1 expression exhibit en-
hanced growth and multiple organ enlargement (19, 35, 47).
The enhanced organ size was shown to be due to an increase
in cell number in those tissues studied, with no significant
increase in cell size, suggesting Akt modulates cell soma size
through mTOR pathway activation and not p27Kip1. In AMOG-
expressing cells, we did not find any reproducible changes in
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p27Kip1 expression (data not shown), suggesting that mTOR/
S6K pathway activation is the primary mechanism involved in
AMOG-induced cell size regulation. Similarly, we found no
differences in the rates of programmed cell death, as deter-
mined by monitoring activation of the apoptotic marker cas-
pase 3, in AMOG-expressing cells (data not shown), despite
the role for Akt in regulating apoptosis (9). These data suggest
that the input to Akt specifically regulates the activation of
downstream effectors. Similar pathway specificity has been ob-
served in cells in which Akt is activated by PIKE-A overex-
pression. While Akt is hyperphosphorylated by PIKE-A and
the rates of apoptosis are robustly decreased, PIKE-A does not
appear to influence cell size regulation (2, 54).
Our data suggest that AMOG-mediated activation of mTOR
and its downstream effectors occurs independently of tuberin/
hamartin signaling (Fig. 6C). This is consistent with previous
observations in Drosophila showing that the effects of Pten and
Tsc1 deletion on cell size control are synergistic (63) and fur-
ther supports tuberin/hamartin-independent roles of Akt in
cell size control. Unlike our observations of hamartin-deficient
cells (68), S6 hyperactivation in AMOG-expressing cells occurs
independently of Rheb activation. Collectively, these data sup-
port tuberin/hamartin-dependent and -independent mecha-
nisms of Akt-mediated regulation of mTOR signaling and sug-
gest that the molecular input regulating Akt phosphorylation
differentially influences Akt-dependent pathways, contributing
to unique cellular phenotypes.
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